NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease (NCT07305818)
A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Who can join: Review the eligibility criteria below.
Location: Site # 1111 — Torrance, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Site # 1111 — Torrance, California
- Site # 1101 — Hollywood, Florida
- Site # 1112 — Miami, Florida
- Site # 1109 — Wesley Chapel, Florida
- Site # 1107 — Boston, Massachusetts
- Site # 1102 — Rochester, Minnesota
- Site # 1106 — Morehead City, North Carolina
- Site # 1104 — Columbus, Ohio
- Site # 1108 — Philadelphia, Pennsylvania
- Site # 1113 — DeSoto, Texas
- Site # 1105 — Webster, Texas
- Site # 2205 — A Coruña,
- Site # 2204 — Barcelona,
- Site # 2206 — Barcelona,
- Site # 2201 — Seville,
📞 Contact the Study Coordinator
Phone: (339) 255-3030
Email: clinicaltrials@meridabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Graves Disease
- Evaluating an AI Tool for Detecting Thyrotoxic States — San Francisco, California
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease — New Hyde Park, New York
- Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease — Burbank, California
- Preoperative Corticosteroids in Autoimmune Thyroid Disease — Indianapolis, Indiana
- Study of BHV-1300 in Graves' Disease — South Gate, California
Explore by condition: All Graves Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.